首页 > 最新文献

The American journal of pediatric hematology/oncology最新文献

英文 中文
Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. 偶然发现的肾上腺皮质癌儿童中p53肿瘤抑制基因的新种系突变。
G H Grayson, S Moore, B G Schneider, V Saldivar, C H Hensel

Purpose: We report a case of adrenal cortical carcinoma in an infant, which was incidentally discovered by renal sonography after a urinary tract infection. The previous death of a sibling after rhabdomyosarcoma in infancy prompted a search for a heritable p53 tumor suppressor gene mutation in this family.

Patients and methods: Starting with frozen adrenal carcinoma tissue, polymerase chain reaction (PCR) amplification followed by direct sequencing of exons 4-8 of p53 was used to search for a mutation. When a mutation was identified in exon 6 of the tumor p53 sequence, PCR amplification and direct sequencing of exon 6 alone was then performed on DNA from peripheral blood lymphocytes (PBLs) of all immediate family members to determine whether a germline mutation was present. A different set of primers was used by a second laboratory at our institution to independently confirm the presence of the mutation in the adrenal carcinoma and in paraffin-embedded rhabdomyosarcoma tissue of the deceased sibling.

Results: A C-to-T transition was identified at a CpG site in codon 196 resulting in a change from arginine to a stop codon (CGA to TGA). The identical mutation, present as the sole p53 allele in the tumor DNA samples and in the heterozygous state with wild type p53 allele in DNA from PBLs (germline), was found in the adrenal carcinoma, the rhabdomyosarcoma, and the PBLs of the tumor-bearing child and her healthy father and 5-year-old brother. This nonsense mutation of p53 has never before been reported in the germline. The extended pedigree showed only one known additional cancer.

Conclusions: A novel germline p53 mutation was identified by investigation of a sibling pair with cancers associated with the Li-Fraumeni syndrome in a family with an otherwise negative history for cancer. The implications of this case for identification of carriers of p53 germline mutations and their clinical management are discussed.

目的:我们报告一个婴儿肾上腺皮质癌的病例,这是偶然发现肾脏超声检查后尿路感染。先前的兄弟姐妹在婴儿期横纹肌肉瘤后死亡,促使人们在这个家族中寻找可遗传的p53肿瘤抑制基因突变。患者和方法:从冷冻的肾上腺癌组织开始,采用聚合酶链反应(PCR)扩增,然后直接测序p53的4-8外显子,寻找突变。当发现肿瘤p53序列外显子6突变时,对所有直系亲属外周血淋巴细胞(pbl)的DNA进行PCR扩增和外显子6的直接测序,以确定是否存在种系突变。我们机构的第二个实验室使用了一组不同的引物,独立地证实了在已故兄弟姐妹的肾上腺癌和石蜡包埋横纹肌肉瘤组织中存在突变。结果:在密码子196的CpG位点上发现了一个c到t的转变,导致精氨酸到停止密码子(CGA到TGA)的变化。在肾上腺癌、横纹肌肉瘤和患癌儿童及其健康父亲和5岁弟弟的pbl中发现了相同的突变,作为肿瘤DNA样本中唯一的p53等位基因,并与pbl(种系)DNA中野生型p53等位基因呈杂合状态。这种无意义的p53突变从未在生殖系中被报道过。扩展的谱系只显示了一种已知的额外癌症。结论:一种新的生殖系p53突变是通过调查与Li-Fraumeni综合征相关的癌症家族的兄弟姐妹,其他阴性的癌症史确定。本病例对p53胚系突变携带者的鉴定及其临床管理的意义进行了讨论。
{"title":"Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma.","authors":"G H Grayson,&nbsp;S Moore,&nbsp;B G Schneider,&nbsp;V Saldivar,&nbsp;C H Hensel","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>We report a case of adrenal cortical carcinoma in an infant, which was incidentally discovered by renal sonography after a urinary tract infection. The previous death of a sibling after rhabdomyosarcoma in infancy prompted a search for a heritable p53 tumor suppressor gene mutation in this family.</p><p><strong>Patients and methods: </strong>Starting with frozen adrenal carcinoma tissue, polymerase chain reaction (PCR) amplification followed by direct sequencing of exons 4-8 of p53 was used to search for a mutation. When a mutation was identified in exon 6 of the tumor p53 sequence, PCR amplification and direct sequencing of exon 6 alone was then performed on DNA from peripheral blood lymphocytes (PBLs) of all immediate family members to determine whether a germline mutation was present. A different set of primers was used by a second laboratory at our institution to independently confirm the presence of the mutation in the adrenal carcinoma and in paraffin-embedded rhabdomyosarcoma tissue of the deceased sibling.</p><p><strong>Results: </strong>A C-to-T transition was identified at a CpG site in codon 196 resulting in a change from arginine to a stop codon (CGA to TGA). The identical mutation, present as the sole p53 allele in the tumor DNA samples and in the heterozygous state with wild type p53 allele in DNA from PBLs (germline), was found in the adrenal carcinoma, the rhabdomyosarcoma, and the PBLs of the tumor-bearing child and her healthy father and 5-year-old brother. This nonsense mutation of p53 has never before been reported in the germline. The extended pedigree showed only one known additional cancer.</p><p><strong>Conclusions: </strong>A novel germline p53 mutation was identified by investigation of a sibling pair with cancers associated with the Li-Fraumeni syndrome in a family with an otherwise negative history for cancer. The implications of this case for identification of carriers of p53 germline mutations and their clinical management are discussed.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 4","pages":"341-7"},"PeriodicalIF":0.0,"publicationDate":"1994-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18973275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood idiopathic thrombocytopenic purpura: association with human parvovirus B19 infection. 儿童特发性血小板减少性紫癜:与人细小病毒B19感染有关。
J C Murray, P K Kelley, W R Hogrefe, K L McClain

Purpose: Infection with human parvovirus B19 is the most common cause of transient aplastic crisis in patients with chronic hemolytic anemia. Multiple reports of children with simultaneous B19 infection and thrombocytopenia as well as the known association between experimental B19 infection and thrombocytopenia prompted us to hypothesize that B19 may be associated with childhood idiopathic, or immune, thrombocytopenic purpura (ITP). Because there is a paucity of evidence regarding a viral etiology for ITP, we performed a comprehensive study to explore its possible relationship to B19 infection.

Patients and methods: Thirty-five previously healthy children with ITP were studied prospectively. Bone marrow and peripheral blood were analyzed for B19 DNA using the polymerase chain reaction (PCR). Serum was analyzed for anti-B19 immunoglobulin (Ig) M and IgG antibodies using a B19 VP1 antigen-based enzyme-linked immunosorbent assay. Fourteen healthy children served as controls for peripheral blood PCR and serologic analyses.

Results: The presenting clinical and laboratory features of the study population were typical of classic ITP. Seventeen of the 35 patients (49%) had evidence of B19 DNA in the peripheral blood, bone marrow, or both. Six of 35 (17%) had anti-B19 IgM antibodies. Eight of 35 (23%) were anti-B19 IgG seropositive. The control group had no positive PCR or anti-B19 IgM specimens.

Conclusions: Our results suggest that infection with human parvovirus B19 may be associated with childhood ITP. More investigation is warranted regarding the role of PCR methodology and serologic detection methods in defining B19 pathobiology as it relates to ITP.

目的:人细小病毒B19感染是慢性溶血性贫血患者一过性再生危象的最常见原因。多例同时发生B19感染和血小板减少症的儿童报告,以及已知的实验性B19感染和血小板减少症之间的关联,促使我们假设B19可能与儿童特发性或免疫性血小板减少性紫癜(ITP)有关。由于缺乏关于ITP的病毒病因的证据,我们进行了一项全面的研究,以探索其与B19感染的可能关系。患者和方法:对35例既往健康的ITP患儿进行前瞻性研究。采用聚合酶链反应(PCR)检测骨髓和外周血B19 DNA。采用基于B19 VP1抗原的酶联免疫吸附法检测血清中抗B19免疫球蛋白(Ig) M和IgG抗体。14名健康儿童作为对照组进行外周血PCR和血清学分析。结果:研究人群的临床和实验室表现为典型的ITP。35例患者中有17例(49%)外周血、骨髓或两者均有B19 DNA。35例患者中有6例(17%)有抗b19 IgM抗体。35例患者中8例(23%)血清抗b19 IgG阳性。对照组无PCR阳性和抗b19 IgM标本。结论:我们的研究结果提示,感染人细小病毒B19可能与儿童ITP有关。PCR方法学和血清学检测方法在确定B19与ITP相关的病理生物学方面的作用有待进一步研究。
{"title":"Childhood idiopathic thrombocytopenic purpura: association with human parvovirus B19 infection.","authors":"J C Murray,&nbsp;P K Kelley,&nbsp;W R Hogrefe,&nbsp;K L McClain","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>Infection with human parvovirus B19 is the most common cause of transient aplastic crisis in patients with chronic hemolytic anemia. Multiple reports of children with simultaneous B19 infection and thrombocytopenia as well as the known association between experimental B19 infection and thrombocytopenia prompted us to hypothesize that B19 may be associated with childhood idiopathic, or immune, thrombocytopenic purpura (ITP). Because there is a paucity of evidence regarding a viral etiology for ITP, we performed a comprehensive study to explore its possible relationship to B19 infection.</p><p><strong>Patients and methods: </strong>Thirty-five previously healthy children with ITP were studied prospectively. Bone marrow and peripheral blood were analyzed for B19 DNA using the polymerase chain reaction (PCR). Serum was analyzed for anti-B19 immunoglobulin (Ig) M and IgG antibodies using a B19 VP1 antigen-based enzyme-linked immunosorbent assay. Fourteen healthy children served as controls for peripheral blood PCR and serologic analyses.</p><p><strong>Results: </strong>The presenting clinical and laboratory features of the study population were typical of classic ITP. Seventeen of the 35 patients (49%) had evidence of B19 DNA in the peripheral blood, bone marrow, or both. Six of 35 (17%) had anti-B19 IgM antibodies. Eight of 35 (23%) were anti-B19 IgG seropositive. The control group had no positive PCR or anti-B19 IgM specimens.</p><p><strong>Conclusions: </strong>Our results suggest that infection with human parvovirus B19 may be associated with childhood ITP. More investigation is warranted regarding the role of PCR methodology and serologic detection methods in defining B19 pathobiology as it relates to ITP.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 4","pages":"314-9"},"PeriodicalIF":0.0,"publicationDate":"1994-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18975381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen. 重组人粒细胞集落刺激因子在循环中性粒细胞减少症:使用一个新的3天,一周的方案。
S Jayabose, O Tugal, C Sandoval, K Li

Background: G-CSF has been shown to be beneficial in cyclic neutropenia when given as a daily subcutaneous injection. We investigated the usefulness of a new three-day-a-week regimen.

Methods: A ten year old boy with cyclic neutropenia was initially treated with G-CSF 7 micrograms/kg given on alternate days for seven months. He was then placed on the same dose, given three days a week. The effectiveness of these regimens were assessed by serial CBCs and by the frequency and duration of the symptoms.

Results: The mean absolute neutrophil count (ANC) increased from 1282 before therapy to 11,718/microliters on alternate day regimen and 7716/microliters on three-day-a-week regimen. The nadir ANC improved from 30/microliters before therapy to 546/microliters and 198/microliters on treatment. The duration and frequency of mouth sores were significantly less on therapy, and there was an estimated cost savings of $23,826/year on three-day-a-week regimen compared to a daily regimen.

Conclusion: The three-day-a-week G-CSF regimen is clinically effective and cost saving in the treatment of cyclic neutropenia and should be studied in a larger cohort of patients.

背景:每日皮下注射G-CSF已被证明对循环中性粒细胞减少症有益。我们调查了新的每周三天方案的有效性。方法:1例10岁的循环性中性粒细胞减少症男童,采用G-CSF 7微克/公斤,隔天给药,连续治疗7个月。然后他被放置在相同的剂量,每周三天。这些方案的有效性是通过连续CBCs和症状的频率和持续时间来评估的。结果:平均绝对中性粒细胞计数(ANC)从治疗前的1282增加到隔天治疗组的11718 /微升,每周3天治疗组的7716/微升。最低点ANC从治疗前的30/微升提高到治疗后的546/微升和198/微升。口腔溃疡的持续时间和频率在治疗中明显减少,与每日治疗相比,每周3天的治疗方案估计每年可节省23,826美元。结论:每周三天G-CSF方案治疗循环性中性粒细胞减少症临床有效且节省成本,应在更大的患者队列中进行研究。
{"title":"Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen.","authors":"S Jayabose,&nbsp;O Tugal,&nbsp;C Sandoval,&nbsp;K Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>G-CSF has been shown to be beneficial in cyclic neutropenia when given as a daily subcutaneous injection. We investigated the usefulness of a new three-day-a-week regimen.</p><p><strong>Methods: </strong>A ten year old boy with cyclic neutropenia was initially treated with G-CSF 7 micrograms/kg given on alternate days for seven months. He was then placed on the same dose, given three days a week. The effectiveness of these regimens were assessed by serial CBCs and by the frequency and duration of the symptoms.</p><p><strong>Results: </strong>The mean absolute neutrophil count (ANC) increased from 1282 before therapy to 11,718/microliters on alternate day regimen and 7716/microliters on three-day-a-week regimen. The nadir ANC improved from 30/microliters before therapy to 546/microliters and 198/microliters on treatment. The duration and frequency of mouth sores were significantly less on therapy, and there was an estimated cost savings of $23,826/year on three-day-a-week regimen compared to a daily regimen.</p><p><strong>Conclusion: </strong>The three-day-a-week G-CSF regimen is clinically effective and cost saving in the treatment of cyclic neutropenia and should be studied in a larger cohort of patients.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 4","pages":"338-40"},"PeriodicalIF":0.0,"publicationDate":"1994-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18533245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital mesoblastic nephroma with metastasis to the brain: a case report. 先天性间母细胞肾瘤伴脑转移1例。
A A Ali, J L Finlay, W L Gerald, P Nisen, N S Rosenfield, M P LaQuaglia, M Spillman, B O'Mally, R Fraser
{"title":"Congenital mesoblastic nephroma with metastasis to the brain: a case report.","authors":"A A Ali,&nbsp;J L Finlay,&nbsp;W L Gerald,&nbsp;P Nisen,&nbsp;N S Rosenfield,&nbsp;M P LaQuaglia,&nbsp;M Spillman,&nbsp;B O'Mally,&nbsp;R Fraser","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 4","pages":"361-4"},"PeriodicalIF":0.0,"publicationDate":"1994-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18973279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. 自体外周血细胞移植治疗晚期神经母细胞瘤。
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00003
A Di Caro, B Bostrom, T J Moss, J Neglia, N K Ramsay, J Smith, L C Sasky

Purpose: We review the experience with autologous peripheral blood cell transplantation (APBCT) in children with neuroblastoma at the University of Minnesota.

Patients and methods: Aspects of peripheral blood cell collection and use in nine patients who had advanced neuroblastoma (eight Evans stage IV, 1 stage III), who were median age 4 years (range 10 months-22 years) and who were treated with high-dose chemotherapy without total body irradiation and APBCT between September 1987 and December 1989 are reviewed.

Results: A median of 4.8 x 10(8) (range 3.3-8.9) mononuclear cells per kilogram of body weight were obtained by a median of six (range four-eight) collections. In vitro assay of granulocyte-monocyte colony-forming cells (CFU-GM) demonstrated a median of 3.6 x 10(4) (range 0.7-7.8) CFU-GM/kg of body weight. After APBCT, granulocyte recovery (absolute neutrophil count > 500 x 10(6)/L) occurred at a median of 28 days (range 14-72) and platelet recovery (> 150 x 10(9)/L) occurred at a median of 34 days (range 19-202). All patients but one, who had progressive disease, were transplanted with residual disease. Immunocytological analysis of peripheral blood stem cell harvest showed the presence of circulating neuroblastoma cells in three of nine patients, all of whom had minimal marrow residual disease by biopsy. One patient is still alive with no evidence of disease after 5 years. The others died of recurrent neuroblastoma a median of 14 months (range 3-29) after transplant.

Conclusion: APBCT is safe and effective for hematopoietic reconstitution after high-dose chemotherapy, and may be useful when a bone marrow harvest cannot be performed because of prior pelvic radiation or minimal residual bone marrow metastasis. Immunocytological methods to ensure that the product is free of tumor contamination should be performed.

目的:我们回顾了明尼苏达大学自体外周血细胞移植(APBCT)治疗儿童神经母细胞瘤的经验。患者和方法:回顾了1987年9月至1989年12月期间9例晚期神经母细胞瘤患者(8例Evans期,1例III期)的外周血收集和使用情况,这些患者中位年龄为4岁(范围10个月-22岁),接受了大剂量化疗,无全身照射和APBCT治疗。结果:中位数为4.8 x 10(8)(范围3.3-8.9)单个核细胞每公斤体重通过中位数6(范围4 -8)收集获得。粒细胞-单核细胞集落形成细胞(CFU-GM)的体外测定显示,中位数为3.6 × 10(4)(范围0.7-7.8)CFU-GM/kg体重。APBCT后,粒细胞恢复(绝对中性粒细胞计数> 500 × 10(6)/L)的中位时间为28天(范围14-72),血小板恢复(> 150 × 10(9)/L)的中位时间为34天(范围19-202)。除了一名病情进展的患者外,所有患者都移植了残留病变。外周血干细胞采集的免疫细胞学分析显示,9例患者中有3例存在循环神经母细胞瘤细胞,所有患者活检均有最小的骨髓残留疾病。一名患者在5年后仍然活着,没有任何疾病迹象。其他患者在移植后平均14个月(范围3-29)死于复发性神经母细胞瘤。结论:APBCT在大剂量化疗后的造血重建中是安全有效的,当由于先前盆腔放疗或少量残留骨髓转移而无法进行骨髓采集时可能是有用的。应采用免疫细胞学方法确保产品无肿瘤污染。
{"title":"Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma.","authors":"A Di Caro,&nbsp;B Bostrom,&nbsp;T J Moss,&nbsp;J Neglia,&nbsp;N K Ramsay,&nbsp;J Smith,&nbsp;L C Sasky","doi":"10.1097/00043426-199408000-00003","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00003","url":null,"abstract":"<p><strong>Purpose: </strong>We review the experience with autologous peripheral blood cell transplantation (APBCT) in children with neuroblastoma at the University of Minnesota.</p><p><strong>Patients and methods: </strong>Aspects of peripheral blood cell collection and use in nine patients who had advanced neuroblastoma (eight Evans stage IV, 1 stage III), who were median age 4 years (range 10 months-22 years) and who were treated with high-dose chemotherapy without total body irradiation and APBCT between September 1987 and December 1989 are reviewed.</p><p><strong>Results: </strong>A median of 4.8 x 10(8) (range 3.3-8.9) mononuclear cells per kilogram of body weight were obtained by a median of six (range four-eight) collections. In vitro assay of granulocyte-monocyte colony-forming cells (CFU-GM) demonstrated a median of 3.6 x 10(4) (range 0.7-7.8) CFU-GM/kg of body weight. After APBCT, granulocyte recovery (absolute neutrophil count > 500 x 10(6)/L) occurred at a median of 28 days (range 14-72) and platelet recovery (> 150 x 10(9)/L) occurred at a median of 34 days (range 19-202). All patients but one, who had progressive disease, were transplanted with residual disease. Immunocytological analysis of peripheral blood stem cell harvest showed the presence of circulating neuroblastoma cells in three of nine patients, all of whom had minimal marrow residual disease by biopsy. One patient is still alive with no evidence of disease after 5 years. The others died of recurrent neuroblastoma a median of 14 months (range 3-29) after transplant.</p><p><strong>Conclusion: </strong>APBCT is safe and effective for hematopoietic reconstitution after high-dose chemotherapy, and may be useful when a bone marrow harvest cannot be performed because of prior pelvic radiation or minimal residual bone marrow metastasis. Immunocytological methods to ensure that the product is free of tumor contamination should be performed.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"200-6"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18911614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Megakaryocyte growth in vitro predicts outcome in idiopathic thrombocytopenic purpura. 巨核细胞体外生长预测特发性血小板减少性紫癜的预后。
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00002
H Gerritsma, A Schmid, A R Luethy, K Leibundgut, E Gugler, H P Wagner, A Hirt

Purpose: The impact of megakaryocyte growth in vitro on clinical data, especially outcome, was studied in 25 consecutive children with idiopathic thrombocytopenic purpura (ITP).

Patients and methods: Twenty children with untreated de novo ITP and five children with pretreated ITP were evaluated. The number of megakaryocyte colonies (cloning efficiency), the mean cell number per colony (mitotic amplification) and the percentages of polyploid megakaryocytes after 7 and 12 days in culture (relative size of the endomitotic compartment) were determined in two separate clonal assays. The culture data were related to clinical findings and outcome of the thrombocytopenia.

Results: The mean cell number per megakaryocyte colony was significantly correlated with the observed increase in the platelet count 5 days after starting therapy (n = 23; r = 0.642), and a significant negative correlation was found between the relative size of the endomitotic compartment and the duration of thrombocytopenia after bone marrow culture analysis (n = 25; r = -0.503). If all 25 children with ITP (untreated de novo and pretreated ITP) were considered, a normal frequency of polyploid megakaryocytes was associated with a duration of ITP for < 6 months in 14 of 16 cases, whereas an impaired polyploidization predicted a persistence of ITP for > 6 months in 9 of 9 cases (p < 0.0005); if only children with untreated de novo ITP (n = 20) were considered, 13 of 15 children with a normal polyploidization had an acute course of their ITP and 5 of 5 children with an impaired polyploidization developed chronic ITP (p < 0.003).

Conclusions: The results in this small group of patients suggest that the assessment of the relative size of the endomitotic compartment after 7 and 12 days in plasma clot culture actually appears to be the best method for predicting a chronic course in children with ITP.

目的:对连续25例特发性血小板减少性紫癜(ITP)患儿进行体外巨核细胞生长对临床数据尤其是预后的影响研究。患者和方法:对20例未经治疗的新生ITP患儿和5例经治疗的ITP患儿进行评估。巨核细胞的集落数(克隆效率)、每集落的平均细胞数(有丝分裂扩增)以及培养7天和12天后多倍体巨核细胞的百分比(有丝分裂室的相对大小)通过两次单独的克隆测定来确定。培养数据与血小板减少症的临床表现和预后有关。结果:每个巨核细胞集落的平均细胞数与开始治疗后5天观察到的血小板计数增加显著相关(n = 23;R = 0.642),骨髓培养分析后发现内膜腔室的相对大小与血小板减少持续时间呈显著负相关(n = 25;R = -0.503)。如果考虑所有25名ITP患儿(未经治疗的新生ITP和预先治疗的ITP), 16例中有14例多倍体巨核细胞正常频率与ITP持续时间< 6个月相关,而9例中有9例多倍体受损预示ITP持续时间> 6个月(p < 0.0005);如果只考虑未经治疗的新生ITP儿童(n = 20), 15名正常多倍体儿童中有13名发生急性ITP, 5名多倍体受损儿童中有5名发生慢性ITP (p < 0.003)。结论:这一小群患者的结果表明,在血浆凝块培养7天和12天后评估内膜腔室的相对大小实际上似乎是预测ITP儿童慢性病程的最佳方法。
{"title":"Megakaryocyte growth in vitro predicts outcome in idiopathic thrombocytopenic purpura.","authors":"H Gerritsma,&nbsp;A Schmid,&nbsp;A R Luethy,&nbsp;K Leibundgut,&nbsp;E Gugler,&nbsp;H P Wagner,&nbsp;A Hirt","doi":"10.1097/00043426-199408000-00002","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00002","url":null,"abstract":"<p><strong>Purpose: </strong>The impact of megakaryocyte growth in vitro on clinical data, especially outcome, was studied in 25 consecutive children with idiopathic thrombocytopenic purpura (ITP).</p><p><strong>Patients and methods: </strong>Twenty children with untreated de novo ITP and five children with pretreated ITP were evaluated. The number of megakaryocyte colonies (cloning efficiency), the mean cell number per colony (mitotic amplification) and the percentages of polyploid megakaryocytes after 7 and 12 days in culture (relative size of the endomitotic compartment) were determined in two separate clonal assays. The culture data were related to clinical findings and outcome of the thrombocytopenia.</p><p><strong>Results: </strong>The mean cell number per megakaryocyte colony was significantly correlated with the observed increase in the platelet count 5 days after starting therapy (n = 23; r = 0.642), and a significant negative correlation was found between the relative size of the endomitotic compartment and the duration of thrombocytopenia after bone marrow culture analysis (n = 25; r = -0.503). If all 25 children with ITP (untreated de novo and pretreated ITP) were considered, a normal frequency of polyploid megakaryocytes was associated with a duration of ITP for < 6 months in 14 of 16 cases, whereas an impaired polyploidization predicted a persistence of ITP for > 6 months in 9 of 9 cases (p < 0.0005); if only children with untreated de novo ITP (n = 20) were considered, 13 of 15 children with a normal polyploidization had an acute course of their ITP and 5 of 5 children with an impaired polyploidization developed chronic ITP (p < 0.003).</p><p><strong>Conclusions: </strong>The results in this small group of patients suggest that the assessment of the relative size of the endomitotic compartment after 7 and 12 days in plasma clot culture actually appears to be the best method for predicting a chronic course in children with ITP.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"194-9"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19031469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Successful treatment of multisystem Langerhans cell histiocytosis (histiocytosis X) with etoposide. 依托泊苷成功治疗多系统朗格汉斯细胞组织细胞病(X型组织细胞病)。
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00017
L C Yu, S Shenoy, K Ward, R P Warrier

Purpose: Langerhans cell histiocytosis (LCH) in its disseminated form usually occurs in the very young, and has a fulminant, rapidly progressive, and fatal course despite different forms of therapy.

Patients and methods: We treated two patients, who had failed on vinblastine treatment, with i.v. etoposide (VP-16) at a dose of 150 mg/kg/day for 3 days. Patient I, 8 months of age, presented with failure to thrive and huge bilateral granulomatous lesions of the external auditory canal with erosion and extensive destruction of the petrous pyramids and mastoid area. Patient II, 20 months of age, presented with widespread purpuric skin rash, hepatosplenomegaly, and bone marrow involvement.

Results: Both patients sustained complete remission (CR) following three to six courses of VP-16 and continued to be in unmaintained CR for > 48 months from diagnosis. No major toxicity was noted.

Conclusions: Etoposide (VP-16), an epipodophyllotoxin known for its usefulness in the treatment of malignancies of the monocyte/macrophage lineage, appears to be an effective treatment for the severe multisystem (disseminated) LCH of childhood and should be strongly considered as front-line therapy for this subgroup of patients with poor prognostic factors.

目的:播散性朗格汉斯细胞组织细胞增多症(LCH)通常发生在非常年轻的时候,尽管有不同的治疗形式,但它具有暴发性、快速进展和致命的过程。患者和方法:我们对两例长春花碱治疗失败的患者静脉注射依托泊苷(VP-16),剂量为150 mg/kg/天,持续3天。患者1,8个月大,表现为发育不良,双侧外耳道巨大肉芽肿病变,伴石状锥体和乳突区糜烂和广泛破坏。患者2,20个月大,表现为广泛的紫癜性皮疹,肝脾肿大,骨髓受累。结果:两例患者在接受3 - 6个疗程的VP-16治疗后均获得完全缓解(CR),并在诊断后的48个月内持续处于非维持CR状态。没有发现重大毒性。结论:依托泊苷(VP-16)是一种以治疗单核/巨噬细胞系恶性肿瘤而闻名的表皮毒素,似乎是儿童严重多系统(弥散性)LCH的有效治疗方法,应强烈考虑将其作为预后不良患者亚组的一线治疗方法。
{"title":"Successful treatment of multisystem Langerhans cell histiocytosis (histiocytosis X) with etoposide.","authors":"L C Yu,&nbsp;S Shenoy,&nbsp;K Ward,&nbsp;R P Warrier","doi":"10.1097/00043426-199408000-00017","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00017","url":null,"abstract":"<p><strong>Purpose: </strong>Langerhans cell histiocytosis (LCH) in its disseminated form usually occurs in the very young, and has a fulminant, rapidly progressive, and fatal course despite different forms of therapy.</p><p><strong>Patients and methods: </strong>We treated two patients, who had failed on vinblastine treatment, with i.v. etoposide (VP-16) at a dose of 150 mg/kg/day for 3 days. Patient I, 8 months of age, presented with failure to thrive and huge bilateral granulomatous lesions of the external auditory canal with erosion and extensive destruction of the petrous pyramids and mastoid area. Patient II, 20 months of age, presented with widespread purpuric skin rash, hepatosplenomegaly, and bone marrow involvement.</p><p><strong>Results: </strong>Both patients sustained complete remission (CR) following three to six courses of VP-16 and continued to be in unmaintained CR for > 48 months from diagnosis. No major toxicity was noted.</p><p><strong>Conclusions: </strong>Etoposide (VP-16), an epipodophyllotoxin known for its usefulness in the treatment of malignancies of the monocyte/macrophage lineage, appears to be an effective treatment for the severe multisystem (disseminated) LCH of childhood and should be strongly considered as front-line therapy for this subgroup of patients with poor prognostic factors.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"275-7"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19035109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Does weight for height have prognostic significance in children with acute lymphoblastic leukemia? 体重身高对急性淋巴细胞白血病患儿预后有影响吗?
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00007
J J Reilly, I Odame, J H McColl, P J McAllister, B E Gibson, B A Wharton

Purpose: We tested the hypothesis that weight for height, a simple index of nutritional status, is related to prognosis in childhood acute lymphoblastic leukemia (ALL).

Patients and methods: The study population was composed of 78 children with ALL tested at one U.K. center on the same protocol (UKALL-X). Outcome measures were relapse/no relapse and time to first relapse. Influence of weight for height, expressed as standard deviation scores, was tested using survival analysis in a retrospective design.

Results: The weight-for-height standard deviation score had a significant influence on time until first relapse (log ranks test, p = 0.012), with the highest risk of early relapse in children at the lower end of the weight-for-height distribution.

Conclusions: The results suggest that weight for height does have an influence on outcome in ALL, but the mechanism is unclear and the finding requires confirmation by larger scale prospective studies.

目的:我们验证了体重与身高(营养状况的简单指标)与儿童急性淋巴细胞白血病(ALL)预后相关的假设。患者和方法:研究人群由78名患有ALL的儿童组成,他们在英国的一个中心接受了相同的治疗方案(UKALL-X)。结局指标为复发/无复发和首次复发时间。体重对身高的影响,以标准偏差分数表示,采用回顾性设计的生存分析进行检验。结果:身高体重标准差评分对首次复发时间有显著影响(对数秩检验,p = 0.012),儿童早期复发风险最高的是身高体重分布的下端。结论:研究结果表明,身高体重对急性淋巴细胞白血病的预后有影响,但其机制尚不清楚,这一发现需要更大规模的前瞻性研究来证实。
{"title":"Does weight for height have prognostic significance in children with acute lymphoblastic leukemia?","authors":"J J Reilly,&nbsp;I Odame,&nbsp;J H McColl,&nbsp;P J McAllister,&nbsp;B E Gibson,&nbsp;B A Wharton","doi":"10.1097/00043426-199408000-00007","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00007","url":null,"abstract":"<p><strong>Purpose: </strong>We tested the hypothesis that weight for height, a simple index of nutritional status, is related to prognosis in childhood acute lymphoblastic leukemia (ALL).</p><p><strong>Patients and methods: </strong>The study population was composed of 78 children with ALL tested at one U.K. center on the same protocol (UKALL-X). Outcome measures were relapse/no relapse and time to first relapse. Influence of weight for height, expressed as standard deviation scores, was tested using survival analysis in a retrospective design.</p><p><strong>Results: </strong>The weight-for-height standard deviation score had a significant influence on time until first relapse (log ranks test, p = 0.012), with the highest risk of early relapse in children at the lower end of the weight-for-height distribution.</p><p><strong>Conclusions: </strong>The results suggest that weight for height does have an influence on outcome in ALL, but the mechanism is unclear and the finding requires confirmation by larger scale prospective studies.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"225-30"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19031393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 46
The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. 格拉司琼在抗癌化疗期间标准止吐治疗失败的儿童癌症患者中的疗效和安全性。
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00008
S J Jacobson, R W Shore, M Greenberg, S P Spielberg

Purpose: This study was undertaken to evaluate the safety and efficacy of granisetron (a 5-hydroxytryptamine. antagonist) in children with malignant disease who had previously experienced unacceptable nausea and vomiting and/or adverse effects associated with standard antiemetic therapy.

Patients and methods: Thirty children 3-18 years of age who were receiving anticancer chemotherapy were enrolled in the study. Patients received a prophylactic dose of granisetron before chemotherapy and two subsequent doses as needed. If further antiemetics were required, standard therapy was given and those patients were classified as treatment failures. Patients received granisetron during one to three cycles of chemotherapy; a total of 66 courses were given.

Results: Eighty-seven percent of patients had good control of nausea and vomiting with granisetron alone; 90% of patients elected to receive granisetron with subsequent chemotherapy. No loss of efficacy was noted with repeated cycles in 21 patients. No serious adverse events occurred.

Conclusions: Intravenous granisetron (20 micrograms/kg/dose) appears to be a safe and effective drug for pediatric patients receiving emetogenic chemotherapy.

目的:本研究旨在评价格拉司琼(一种5-羟色胺)的安全性和有效性。拮抗剂)用于恶性疾病儿童,这些儿童以前经历过不可接受的恶心和呕吐和/或与标准止吐治疗相关的不良反应。患者和方法:30名3-18岁正在接受抗癌化疗的儿童被纳入研究。患者在化疗前接受一剂预防剂量的格拉司琼,随后根据需要接受两剂。如果需要进一步的止吐药,则给予标准治疗,并将这些患者归类为治疗失败。患者在1 - 3个化疗周期内接受格拉司琼;共开设了66门课程。结果:87%的患者单用格拉司琼对恶心呕吐控制良好;90%的患者选择在化疗后接受格拉司琼。21例患者在重复疗程中未发现疗效下降。未发生严重不良事件。结论:静脉注射格拉司琼(20微克/公斤/剂量)对于接受致吐性化疗的儿科患者似乎是一种安全有效的药物。
{"title":"The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy.","authors":"S J Jacobson,&nbsp;R W Shore,&nbsp;M Greenberg,&nbsp;S P Spielberg","doi":"10.1097/00043426-199408000-00008","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00008","url":null,"abstract":"<p><strong>Purpose: </strong>This study was undertaken to evaluate the safety and efficacy of granisetron (a 5-hydroxytryptamine. antagonist) in children with malignant disease who had previously experienced unacceptable nausea and vomiting and/or adverse effects associated with standard antiemetic therapy.</p><p><strong>Patients and methods: </strong>Thirty children 3-18 years of age who were receiving anticancer chemotherapy were enrolled in the study. Patients received a prophylactic dose of granisetron before chemotherapy and two subsequent doses as needed. If further antiemetics were required, standard therapy was given and those patients were classified as treatment failures. Patients received granisetron during one to three cycles of chemotherapy; a total of 66 courses were given.</p><p><strong>Results: </strong>Eighty-seven percent of patients had good control of nausea and vomiting with granisetron alone; 90% of patients elected to receive granisetron with subsequent chemotherapy. No loss of efficacy was noted with repeated cycles in 21 patients. No serious adverse events occurred.</p><p><strong>Conclusions: </strong>Intravenous granisetron (20 micrograms/kg/dose) appears to be a safe and effective drug for pediatric patients receiving emetogenic chemotherapy.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"231-5"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19031394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Pain in children and adolescents with sickle cell anemia: a prospective study utilizing self-reporting. 患有镰状细胞性贫血的儿童和青少年疼痛:一项采用自我报告的前瞻性研究。
Pub Date : 1994-08-01 DOI: 10.1097/00043426-199408000-00006
K A Sporrer, S M Jackson, S Agner, J Laver, M R Abboud

Purpose: The purpose of this study was to characterize pain reporting among children with sickle cell anemia (SCA) experiencing painful vaso-occlusive crises. These patients were managed according to a protocol based on self-reports of pain.

Patients and methods: Seventeen children (3-18 years) with SCA (Hb SS) who were admitted for painful crisis were asked to report their pain according to a rating scale of 0-5. These pain scores were analyzed according to the Mann-Whitney method to determine differences in pain reporting among young children (3-12 years) and adolescents (13-18 years). The Kruskal-Wallis method was utilized to determine relationships between the number of painful body sites, reported pain scores, and length of hospital stay.

Results: Children (3-12 years) reported significantly less severe pain than adolescents (13-18 years) (p < 0.01). The severity of pain reported was not related to the number of painful sites. However, the length of stay was significantly longer in patients with greater numbers of painful sites (p < 0.05). Patients who reported pain scores of > 2 at 24 h had significantly longer periods of hospitalization.

Conclusion: A protocol based upon self-reports of pain was successfully utilized to provide analgesia during painful crises. There were characteristic differences between young children and adolescents in self-reporting of pain. Pain scores may be helpful in predicting length of hospitalization for painful crises.

目的:本研究的目的是描述镰状细胞性贫血(SCA)儿童经历疼痛的血管闭塞危象的疼痛报告。这些患者根据基于自我疼痛报告的方案进行管理。患者和方法:17例因疼痛危象入院的SCA (Hb SS)患儿(3-18岁),按0-5分量表报告疼痛情况。根据Mann-Whitney方法对这些疼痛评分进行分析,以确定幼儿(3-12岁)和青少年(13-18岁)疼痛报告的差异。采用Kruskal-Wallis方法确定疼痛部位的数量、报告的疼痛评分和住院时间之间的关系。结果:儿童(3-12岁)报告的剧烈疼痛明显少于青少年(13-18岁)(p < 0.01)。报告的疼痛严重程度与疼痛部位的数量无关。然而,疼痛部位较多的患者住院时间明显更长(p < 0.05)。24小时疼痛评分> 2的患者住院时间明显延长。结论:一种基于自我疼痛报告的方案成功地应用于疼痛危机期间的镇痛。幼儿和青少年在自我报告疼痛方面存在特征差异。疼痛评分可能有助于预测疼痛危机的住院时间。
{"title":"Pain in children and adolescents with sickle cell anemia: a prospective study utilizing self-reporting.","authors":"K A Sporrer,&nbsp;S M Jackson,&nbsp;S Agner,&nbsp;J Laver,&nbsp;M R Abboud","doi":"10.1097/00043426-199408000-00006","DOIUrl":"https://doi.org/10.1097/00043426-199408000-00006","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to characterize pain reporting among children with sickle cell anemia (SCA) experiencing painful vaso-occlusive crises. These patients were managed according to a protocol based on self-reports of pain.</p><p><strong>Patients and methods: </strong>Seventeen children (3-18 years) with SCA (Hb SS) who were admitted for painful crisis were asked to report their pain according to a rating scale of 0-5. These pain scores were analyzed according to the Mann-Whitney method to determine differences in pain reporting among young children (3-12 years) and adolescents (13-18 years). The Kruskal-Wallis method was utilized to determine relationships between the number of painful body sites, reported pain scores, and length of hospital stay.</p><p><strong>Results: </strong>Children (3-12 years) reported significantly less severe pain than adolescents (13-18 years) (p < 0.01). The severity of pain reported was not related to the number of painful sites. However, the length of stay was significantly longer in patients with greater numbers of painful sites (p < 0.05). Patients who reported pain scores of > 2 at 24 h had significantly longer periods of hospitalization.</p><p><strong>Conclusion: </strong>A protocol based upon self-reports of pain was successfully utilized to provide analgesia during painful crises. There were characteristic differences between young children and adolescents in self-reporting of pain. Pain scores may be helpful in predicting length of hospitalization for painful crises.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"16 3","pages":"219-24"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00043426-199408000-00006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19031392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
期刊
The American journal of pediatric hematology/oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1